Since the renoprotective effects of angiotensin-converting enzyme (ACE) inhibitors before overt hypertension in AS were shown [30], renin–angiotensin system (RAS) inhibitor treatment should be initiated even if the patient was not hypertensive. This evidence concerns the gene ACE and Hypertension.